| Document |
Document Title |
|
WO/1997/019081A1 |
Metalated bacteriochlorophylls of the formula [M]-BChl, wherein M is a metal atom selected from divalent Pd, Co, Ni, Cu, Zn and Mn, trivalent Fe, Mn and Cr, and tetravalent Sn and Pt, and Bchl represents the residue of a demetalated natu...
|
|
WO/1997/017092A1 |
The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of 1-amino-cycloalkyl-1-carboxylic acids, namely, their rapid uptake and prol...
|
|
WO/1997/016210A1 |
Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds ...
|
|
WO/1997/014445A1 |
This invention presents a series of novel tropane-based derivatives complexed with either technetium or rhenium that are specific for central nervous system receptors, in particular, dopamine or serotonin receptors. The compounds of the ...
|
|
WO/1997/012850A2 |
New compounds have the general formula (I): M - L, in which M stands for a radio-isotope of Tc or Re and L stands for a ligand having the general formula (II): B-CR1R2-(CR3R4)n=1,2-S-CHR5-CHR6-SO2-NH-CR7R8-(CR9R10)m=1,2-
D, in which R1, ...
|
|
WO/1997/012636A2 |
The invention concerns novel compounds of general formula (I), M-L, in which M stands for a radioisotope of Tc or Re and L stands for a ligand of general formula (II) R1S-CR2R3-(CR4R5)n=1,2-S-CHR6-CHR7-SO2-NH-(CR8R9)m=1,2-CO-B in which R...
|
|
WO/1997/010852A2 |
The invention pertains to novel compounds of the general formula (I): M - L in which M stands for a radioisotope of Tc or Re, L stands for a ligand of the general formula (II): B-CO-(CR1R2)n=1,2-S-CHR3-CHR4-SO2-NH-CR5R6-(CR7R8)m=1,2-SR9 ...
|
|
WO/1997/010853A2 |
The invention pertains to novel compounds of general formula (I) in which M stands for a radioisotope of Tc or Re, L stands for a ligand of general formula (II) in which R1, R2, R3, R4, R5 and R6 can have different meanings and stand for...
|
|
WO/1997/006824A2 |
Bioconjugates of low molecular weight mimics of superoxide dismutase (SOD) represented by formula (I), wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, R'9, X, Y, Z and n are as defined herein, u...
|
|
WO/1996/040149A1 |
The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form s...
|
|
WO/1996/040148A1 |
The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form s...
|
|
WO/1996/040658A1 |
A process for preparing a substituted polyazamacrocycle is provided which comprises contacting a diamine or triamine and a dicarboxylic acid or ester or anhydride thereof in the presence of a suitable base and a suitable solvent to produ...
|
|
WO/1996/039396A1 |
Low molecular weight mimics of superoxide dismutase (SOD) represented by formula (I), wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9, M, X, Y, Z and n are as defined herein, useful as t...
|
|
WO/1996/031243A1 |
This invention provides novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders, infectious diseases and cancer. The radiopharmaceuticals are comprised of phosphine or arsine ligated te...
|
|
WO/1996/030054A1 |
The invention relates to a zero-charged 99mTc - labelled substance having a serotonin receptor binding activity, wherein the serotonin receptor binding compound is represented by the general formula (I): L - A - B - E, wherein L is a che...
|
|
WO/1996/030056A1 |
A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises a functionalized hydroxyalkyl phosphine ligand and a metal combined with the ligand.
|
|
WO/1996/015136A1 |
The present invention concerns novel maganese (II) carboxylate complexes having utility as disproportionation catalysts and processes for their preparation. The invention provides Mn(II) carboxylate complexes or their binuclear or polynu...
|
|
WO/1996/013504A1 |
A 'beta','beta''-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compound having formula (I) or (II), wherein M is a metal. A novel method for synthesizing the compound of formula (I) or (II) comprises the steps...
|
|
WO/1996/011907A1 |
Method of enhancing the water solubility of dry zinc and/or manganese methionine complex salts by reacting a water soluble zinc and/or manganese salt with methionine in the presence of ferric ion with the amount being between at least 15...
|
|
WO/1996/008311A1 |
The present invention provides a novel synthesis for preparing D4-symmetric chiral porphyrins derived from 1R-(+)-nopinone. The simplicity and flexibility of this synthetic protocol provides an attractive route to this novel class of por...
|
|
WO/1996/008497A1 |
Novel group 4, group 3 or lanthanide metal complexes wherein the metal is in the +3 formal oxidation state containing a cyclic or non-cyclic, non-aromatic, anionic, dienyl ligand group bound to M and having a bridged ligand structure, ca...
|
|
WO/1996/007629A1 |
The invention relates to a compound of general formula (I) wherein: Y is a thio function or a group of formula (a), Z is a carboxy group, a (C1-C4)alkoxycarbonyl group, an aminocarbonyl group, an aminosulphonyl group or a carboxymethylam...
|
|
WO/1996/006101A1 |
A palatable metal amino acid chelate for administration to humans and other warm-blooded animals is disclosed wherein there are sufficient ligands to provide ionic and coordinate covalent bonds equal to the coordination number of the cen...
|
|
WO/1996/003410A1 |
The present invention concerns novel hydrophilic metal complexes and the use thereof as luminescent marker groups in immunoassays.
|
|
WO/1996/003409A1 |
The present invention concerns novel metal complexes with charged linker and the use of such complexes as luminescent marker groups in immunoassays.
|
|
WO/1996/002500A1 |
The invention relates to novel chelate formers containing sulphonamide groups and their metallic chelates of general formula (I) in which n, m, p, V1, V2, V3, V4, X1, X2, X3, R1, R2, R3 and R4 have different meanings, pharmaceutical agen...
|
|
WO/1995/033757A1 |
Preparations of radiolabelled bone scanning agents are improved by adding energy to the reconstituted kit in the form of heat. The preparations may be heated by autoclaving, boiling, microwaving, or sonicating. The improved agent exhibit...
|
|
WO/1995/032192A1 |
The present invention provides aromatic amine substituted metal chelating compounds of formula (I) in which the variables are as defined in the claims, chelates and chelate-targeting moiety conjugates formed from the chelating compounds,...
|
|
WO/1995/031197A1 |
The present invention provides a method for the treatment of diseases by the decomposition of peroxynitrite, preferably decomposition to benign products, comprising the use of a complex which is a selected ligand structure providing a co...
|
|
WO/1995/031425A1 |
The invention includes the synthesis of multivalent metal complexes with boron containing complex organic anions. The complexes include or may include ligands. Complexes capable of being so synthesised are also disclosed as is their use ...
|
|
WO/1995/031221A1 |
This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents,...
|
|
WO/1995/030681A1 |
Single or multi-nuclear metal complexes [LnMmXp]zY, in which M is manganese in the oxidation number (II, III, IV, V and/or VI), copper in the oxidation number (I and/or II), cobalt in the oxidation number (II and/or III) or zinc in the o...
|
|
WO/1995/029669A2 |
A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises either a phosphorous or germanium core and at least two hydrazine groups forming a ligand for bonding to a metal extending from th...
|
|
WO/1995/029924A1 |
A compound, in metal-free or metal complex form of formula (1) to (3) in which R is hydrogen or C1-30 alkyl; X is hydrogen, halogen (preferably Cl or Br) or C1-30 alkyl.
|
|
WO/1995/028968A1 |
The present invention is directed to complexes represented by formula (I) wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, R'9, R10, R11, R12, R13, R14, M, X, Y, Z and N are defined herein for us...
|
|
WO/1995/029180A1 |
Compounds of formula (1) and the metalated forms and salts thereof; wherein n is an integer of 1-4; and wherein each Pi is independently a pyrrole residue of formula (II), wherein each Ria and Rib is independently a noninterfering substi...
|
|
WO/1995/028179A1 |
Paramagnetic metal complexes of 1-(p-n-butylbenzyl)diethylenetriamine pentaacetic acid and pharmaceutically acceptable salts thereof are effective as tissue-specific MRI contrast agents, and in particular as hepatobiliary MRI contrast ag...
|
|
WO/1995/028380A1 |
The present invention provides compounds of formula (I) wherein Z1 and Z2 each represent the atoms necessary to complete a monocyclic or polycyclic carbocyclic or heterocyclic ring system, said Z1 and Z2 independently optionally substitu...
|
|
WO/1995/027701A1 |
Metal-containing steroid mimic complexes are provided. Compositions containing a metal ion incorporated into a steroid skeleton structure and ligands useful in the preparation of such compositions are also provided. The metal ion is pref...
|
|
WO/1995/021172A1 |
A process for enantioselectively epoxidising a prochiral olefin, which process comprises reacting the prochiral olefin with a source of oxygen in the presence of a salen catalyst and a source of an electron donating ligand, characterised...
|
|
WO/1995/019791A1 |
Radiolabeled annexins useful for imaging vascular thrombi are discussed. Methods for making such radiolabeled annexins are also addressed.
|
|
WO/1995/019338A1 |
Novel compounds of formula (I) and novel complexes of these compounds with metals are useful in diagnostic and therapeutic methods, wherein R, R* an Q have the meanings given in the description and one of G, and G2 is -N(R2)2, the other ...
|
|
WO/1995/015979A1 |
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.
|
|
WO1995004552A3 |
|
|
WO/1995/005388A1 |
A compound which can be complexed with 99mTc, has the formula T-R-Y wherein T is a targeting group derived from a molecule T' which has an affinity to a specific body tissue said targeting group essentially retaining the specific affinit...
|
|
WO/1995/005398A1 |
Novel chelating compounds and the corresponding radionuclide metal chelates are useful for radiolabeling proteins such as antibodies, ligands such as biotin and anti-ligands such as streptavidin with radionuclide metals such as 99mTc, 18...
|
|
WO/1995/004552A2 |
The invention concerns ligands, e.g. based on alkylene amine oxime particularly butylene amine oxime ring structures, and radiometal complexes thereof. The radiometal complexes are intrinsically capable of localising in tumours or hypoxi...
|
|
WO/1995/004114A1 |
Tris(isonitrile)copper(I) sulfate complexes and their use in synthetic methods for making radionuclide isonitrile coordination complexes such as [99mTc(1-isocyano-2-methoxy-2-methylpropane)6]+. The coordination complexes are useful as ra...
|
|
WO/1995/003280A1 |
Radionuclide chelating compounds are provided for conjugation to targeting molecules such as proteins, peptides or antibodies. The resulting labelled targeting molecules may be used in diagnosis and therapy.
|
|
WO/1995/003330A1 |
This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labelled radiodiagnostic agents. Specifically, the invention relates to linear peptide derivatives and analogs ...
|
